Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

被引：1

作者：

Spigel, David ^{[1
]}

Pietanza, M. Catherine ^{[2
]}

Bauer, Todd ^{[1
]}

Ready, Neal ^{[3
]}

Morgensztern, Daniel ^{[4
]}

Glisson, Bonnie S. ^{[5
]}

Byers, Lauren Averett ^{[5
]}

Johnson, Melissa ^{[1
]}

Burris, Howard ^{[1
]}

Robert, Francisco ^{[6
]}

Han, Tae ^{[7
]}

Bheddah, Sheila ^{[7
]}

Theiss, Noah ^{[8
]}

Watson, Sky ^{[8
]}

Mathur, Deepan ^{[8
]}

Vennapusa, Bharathi ^{[8
]}

Strickland, Donald ^{[1
]}

Zayed, Hany ^{[7
]}

Dylla, Scott ^{[7
]}

Peng, Stanford ^{[7
]}

Govindan, Ramaswamy ^{[4
]}

Rudin, Charles ^{[9
]}

机构：

[1] Tennessee Oncol PLCC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Abbvie Stemcentrx Llc, San Francisco, CA USA

[8] Roche Diagnost, Tucson, AZ USA

[9] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

clinical trial; Rovalpituzumab tesirine; Delta-like protein 3; SCLC;

D O I：

10.1016/j.jtho.2016.11.252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA05.03

引用

页码：S260 / S261

页数：2

共 48 条

[21] Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer
Yan, Li-Xu
Liu, Yan-Hui
Li, Zhi
Luo, Dong-Lan
Li, Yu-Fa
Yan, Jing-Hai
Zhang, Jia-Tao
Liu, Chao
Liu, Xun-Hua
He, Jiao
ONCOLOGY LETTERS, 2019, 18 (03) : 2254 - 2261
[22] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
Paz-Ares, L.
Owonikoko, T. K.
Johnson, M.
Govindan, R.
Izumi, H.
Lai, V.
Borghaei, H.
Boyer, M.
Boosman, R. J.
Hummel, H-D.
Blackhall, F.
Dowlati, A.
Zhang, Y.
Mukherjee, S.
Sable, B.
Pati, A.
Shetty, A.
Sadraei, N. Hashemi
Champiat, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
[23] Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Zhou, Di
Byers, Lauren A.
Sable, Beate
Smit, Marie-Anne Damiette
Sadraei, Nooshin Hashemi
Dutta, Sandeep
Upreti, Vijay V.
JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 362 - 370
[24] Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
Kuempers, Christiane
Jagomast, Tobias
Krupar, Rosemarie
Paulsen, Finn-Ole
Heidel, Carsten
Ribbat-Idel, Julika
Idel, Christian
Maerkl, Bruno
Anlauf, Martin
Berezowska, Sabina
Tiemann, Markus
Boesmueller, Hans
Fend, Falko
Kalsdorf, Barbara
Bohnet, Sabine
Dreyer, Eva
Sailer, Verena
Kirfel, Jutta
Perner, Sven
FRONTIERS IN MEDICINE, 2021, 8
[25] Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Gray, Jhanelle E.
Heist, Rebecca S.
Starodub, Alexander N.
Camidge, D. Ross
Kio, Ebenezer A.
Masters, Gregory A.
Purcell, W. Thomas
Guarino, Michael J.
Misleh, Jamal
Schneider, Charles J.
Schneider, Bryan J.
Ocean, Allyson
Johnson, Tirrell
Gandhi, Leena
Kalinsky, Kevin
Scheff, Ronald
Messersmith, Wells A.
Govindan, Serengulam V.
Maliakal, Pius P.
Mudenda, Boyd
Wegener, William A.
Sharkey, Robert M.
Goldenberg, David M.
CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5711 - 5719
[26] Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis
Chen, Benchao
Li, Heng
Liu, Chao
Wang, Shuting
Zhang, Feiyue
Zhang, Li
Li, Mingjie
Li, Gaofeng
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[27] PHARMACOKIN ETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Minocha, M.
Thompson, C.
Murphy, A.
Zhou, Y.
Parkes, A.
Chen, X.
Yu, B.
Martinez, P.
Houk, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S68 - S68
[28] Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis
Benchao Chen
Heng Li
Chao Liu
Shuting Wang
Feiyue Zhang
Li Zhang
Mingjie Li
Gaofeng Li
World Journal of Surgical Oncology, 18
[29] A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer
Hipp, Susanne
Voynov, Vladimir
Drobits-Handl, Barbara
Giragossian, Craig
Trapani, Francesca
Nixon, Andrew E.
Scheer, Justin M.
Adam, Paul J.
CLINICAL CANCER RESEARCH, 2020, 26 (19) : 5258 - 5268
[30] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Owonikoko, Taofeek K.
Champiat, Stephane
Johnson, Melissa Lynne
Govindan, Ramaswamy
Izumi, Hiroki
Lai, W. Victoria Victoria
Borghaei, Hossein
Boyer, Michael J.
Boosman, Rene J.
Hummel, Horst-Dieter
Blackhall, Fiona Helen
Reguart, Noemi
Dowlati, Afshin
Zhang, Yiran
Mukherjee, Sujoy
Minocha, Mukul
Zhou, Yanchen
Shetty, Aditya
Sadraei, Nooshin Hashemi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →